Calendario›REGN›REGN17235

REGN17235

Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

Ensayo de REGENERON PHARMACEUTICALS, INC. en Clonal Cytopenia of Undetermined Significance (CCUS) · Low-Risk Myelodysplastic Syndrome (LR-MDS) (del registro, en inglés).

Fase

Fase 1

Estado

Aún sin reclutar

Participantes

52

previstos

Fin del objetivo primario

may 2031

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en sep 2026.

Qué mide

Occurrence of Treatment Emergent Adverse Events (TEAEs) (del registro, en inglés) (hasta 5 años)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study will test a study drug called REGN17235 (the "study drug") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic mutation (SF3B1 Mutation). The study is looking at: * What side effects the study drug might cause * How well the study drug works * How much of the study drug is in the blood at different times * If the body makes antibodies (proteins that attach to substances your body does not recognize) against the study drug; this may cause the study drug to not work as well. * What is the best dose of the study drug to treat CCUS and LR-MDS

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07753148), actualizada en ago 2026.